Type of Assessment:
Maintenance pemetrexed after platinum pemetrexed chemotherapy and survival outcomes in malignant pleural mesothelioma in a multicenter real world study
Scientific Reports 2026 July 15 [Link] Okan Aydin, Zehra Sucuoglu Isleyen, Mert Erciyestepe, Ahmet Emin Ozturk, Sermin Dinc Sonusen, Tugay Atasever, Simay Cokgezer, Ebru Cicek, Ayse Gul Satman Durmaz, Lamia Seker Can, Gozde Balkaya Aykut, Tuba Baydas, Miray Aydogan, Seval Ay Ersoy, Muhammed Mustafa Atci, Kayhan Erturk Abstract Malignant pleural mesothelioma (MPM) is an aggressive…
Read MoreNavigating the Foggy Landscape of Epithelioid Peritoneal Mesothelioma: A Proposed Standardized Institutional Algorithm for Multimodal Management
Cancers 2026 June 30 [Link] Giorgio D’Annibale, Francesco Santullo, Lorenzo Barberis, Claudio Lodoli, Tommaso Partipilo, Giusi Giulia La Manna, Antonia Strippoli, Alexia Spring, Fabio Pacelli, Carlo Abatini Abstract Purpose: Diffuse malignant peritoneal mesothelioma is a rare disease requiring management in specialized referral centers. We report our institutional experience with epithelioid diffuse malignant peritoneal mesothelioma, focusing…
Read MorePrognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
NPJ Precision Oncology 2026 July 9 [Link] Justin M Bader, Ankit Dhiman, Nicole Aguirre, Kwasi Ansere Ofori, Princy Gupta, Hannah Qin, Anup Sharma, Owen Mitchell, Melissa Y Tjota, Aliya N Husain, Michael Drazer, Jane Churpek, Hedy Kindler, Kiran Turaga Abstract Mesothelioma is a rare cancer with poor prognosis. Somatic mutations show prognostic value in smaller…
Read MoreMulticystic peritoneal mesothelioma mimicking recurrent pseudomyxoma peritonei
Journal of Surgical Case Reports 2026 July 7 [Link] Alessia Scarton, Marco Tonello, Elisa Pizzolato, Carola Cenzi, Ivana Cataldo, Vasileios Mourmouras, Pierluigi Pilati, Antonio Sommariva Abstract Multicystic peritoneal mesothelioma (MCPM) is a borderline variant of peritoneal mesothelioma with indolent behaviour but a significant recurrence rate without radical treatment. Due to its rarity, risk factors and…
Read MoreBAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma
Thoracic Cancer 2026 July [Link] Reina Imase, Rie Sakakibara, Susumu Kirimura, Hironori Ishibashi, Kenichi Okubo, Yasunari Miyazaki Abstract Introduction: Reliable predictive biomarkers for immune checkpoint inhibitors (ICIs) in pleural mesothelioma (PM) are lacking. Loss of BRCA1-associated protein 1 (BAP1) is a frequent molecular alteration in PM and may influence the tumor immune microenvironment. We evaluated…
Read MoreProtocol for Mesothelioma Observational study of Risk prediction and Generation of paired benign-meso tissue samples, Including a Nested MRI Substudy (Meso-ORIGINS)
BMJ Open Respiratory Research 2026 July 1 [Link] Mark D J Neilly, Alexandrea MacPherson, Laura Alexander, Nicola Walker, Caroline Kelly, Joshua Roche, Emad Abugassa, Liam Allan, Adeel Ashraf, Avinash Aujayeb, Anna Bibby, Rocco Bilancia, John Corcoran, Mahendran Chetty, Kevin Conroy, Christopher Craig, Rebecca Crook, Alveena D’Souza, Cyrus Daneshvar, Duneesha DeFoneska, Poppy Denniston, Janet Fallon, Katie…
Read MoreFrom Ascites to Malignant Peritoneal Mesothelioma: The Diagnostic Workup of a Rare Tumor
Cancer Diagnosis & Prognosis 2026 July 1 [Link] Mirko Nastasi, Chiara Ferrante, Giuliana Michelis, Enrica Branca, Manuel Ventura, Silvia Novello, Emanuela Laurita Abstract Background/aim: Ascites is a common clinical manifestation of a wide spectrum of heterogeneous underlying conditions. All possible causes of ascites should be considered in the differential diagnosis to ensure an appropriate diagnostic…
Read MoreLong-Term Disease Control With Second-Line Nivolumab Monotherapy in Malignant Pleural Mesothelioma: A Case Report
Cureus 2026 June 1 [Link] Shohei Otsuka, Kei Hiraoka, Nozomu Iwashiro Abstract Nivolumab is recommended as second-line therapy for malignant pleural mesothelioma (MPM); however, durable responses remain uncommon. In addition, combination immune checkpoint inhibitors are frequently limited by immune-related adverse events. A 72-year-old man with epithelioid MPM underwent extrapleural pneumonectomy followed by adjuvant chemotherapy with…
Read MoreImpact of CD73/CD155 Expression on Survival in Resected Epithelial Pleural Mesothelioma: A Retrospective Single-center Study
In Vivo 2026 July-August [Link] Yusuke Nabe, Yasuhiro Fujita, Teppei Hashimoto, Kanji Tanaka, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Natsumasa Nishizawa, Rintaro Oyama, Yohei Honda, Masataka Mori, Hiroki Matsumiya, Masatoshi Kanayama, Akihiro Taira, Masaru Takenaka, Koji Kuroda, Shohei Shimajiri, Fumihiro Tanaka Abstract Background/aim: While CD73 and CD155 are implicated in immune evasion and tumor progression,…
Read MoreCase Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma
Frontiers in Oncology 2026 June 16 [Link] Zijuan Liu, Yating Yan, Caihong Jiang Abstract Background: Primary malignant pericardial mesothelioma (PMPM) is an exceedingly rare and highly malignant tumor that originates in the serosal layer of the pericardium. Currently, there are no specific guidelines for diagnosis and treatment in China and international countries for this disease,…
Read More
Skip to content